What is the current valuation of the US autologous cell-therapy market?

The market valuation was $1350.8 Million in 2024. Read More

What is the projected market size for the US autologous cell-therapy market by 2035?

The market is expected to reach $10000.0 Million by 2035. Read More

What is the expected CAGR for the US autologous cell-therapy market during the forecast period 2025 - 2035?

The expected CAGR is 19.96% during the forecast period. Read More

Which application segment holds the highest valuation in the US autologous cell-therapy market?

The Orthopedics application segment had a valuation of $3000.0 Million. Read More

What are the leading cell types in the US autologous cell-therapy market?

T Cells and Platelet Rich Plasma are leading cell types, with valuations of $3500.0 Million and $4000.0 Million, respectively. Read More

Which end-use segment contributes the most to the US autologous cell-therapy market?

The Hospitals end-use segment contributed $4000.0 Million. Read More

What technology segment is expected to show significant growth in the US autologous cell-therapy market?

The Cell Expansion technology segment is projected to grow, with a valuation of $4000.0 Million. Read More

Who are the key players in the US autologous cell-therapy market?

Key players include Novartis, Gilead Sciences, Bristol-Myers Squibb, and Amgen. Read More

What is the valuation of the Cardiology application segment in the US autologous cell-therapy market?

The Cardiology application segment had a valuation of $2000.0 Million. Read More

How does the valuation of the Dermatology application segment compare to others in the US autologous cell-therapy market?

The Dermatology segment had a valuation of $3500.0 Million, indicating strong market presence. Read More

US Autologous Cell Therapy Market

US Autologous Cell Therapy Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Orthopedics, Dermatology), By Cell Type (Stem Cells, T Cells, Dendritic Cells, Platelet Rich Plasma), By End Use (Hospitals, Clinics, Research Laboratories) and By Technology (Cell Isolation, Cell Expansion, Cryopreservation) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

19.96%

2024 Market Size

$ 1,350.8 Million

2035 Market Size

$ 10,000 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/14133-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Application (USD Million)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Orthopedics
  4. 4.1.4 Dermatology
2. 4.2 Life Sciences, BY Cell Type (USD Million)
  1. 4.2.1 Stem Cells
  2. 4.2.2 T Cells
  3. 4.2.3 Dendritic Cells
  4. 4.2.4 Platelet Rich Plasma
3. 4.3 Life Sciences, BY End-use (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Research Laboratories
4. 4.4 Life Sciences, BY Technology (USD Million)
  1. 4.4.1 Cell Isolation
  2. 4.4.2 Cell Expansion
  3. 4.4.3 Cryopreservation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Celgene (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sangamo Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Celyad Oncology (BE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Vericel Corporation (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY CELL TYPE
4. 6.4 US MARKET ANALYSIS BY END-USE
5. 6.5 US MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY CELL TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY CELL TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY END-USE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END-USE, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USE, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Autologous Cell Therapy Market Segmentation

US Autologous Cell Therapy Market By Application (USD Million, 2025-2035)

Oncology
Cardiology
Orthopedics
Dermatology

US Autologous Cell Therapy Market By Cell Type (USD Million, 2025-2035)

Stem Cells
T Cells
Dendritic Cells
Platelet Rich Plasma

US Autologous Cell Therapy Market By End-use (USD Million, 2025-2035)

Hospitals
Clinics
Research Laboratories

US Autologous Cell Therapy Market By Technology (USD Million, 2025-2035)

Cell Isolation
Cell Expansion
Cryopreservation

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”